A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Cancer Medicine

Alexander M. Aliper²  Victoria P. Frieden-Korovkina¹  Anton Buzdin²  Sergey A. Roumiantsev² 

[1] HiBiotechnology, LLC, Iowa City, Iowa;Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

关键词: Bladder;    bone;    cancer;    colorectal;    G‐CSF;    glioma;    GM‐SF;    lung;    melanoma;    metastasis;    prostate;   

DOI  :  10.1002/cam4.239

来源: Wiley

【 摘 要 】

Abstract

Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) modulate progression of certain solid tumors. The G-CSF- or GM-CSF-secreting cancers, albeit not very common are, however, among the most rapidly advancing ones due to a cytokine-mediated immune suppression and angiogenesis. Similarly, de novo angiogenesis and vasculogenesis may complicate adjuvant use of recombinant G-CSF or GM-CSF thus possibly contributing to a cancer relapse. Rapid diagnostic tools to differentiate G-CSF- or GM-CSF-secreting cancers are not well developed therefore hindering efforts to individualize treatments for these patients. Given an increasing utilization of adjuvant G-/GM-CSF in cancer therapy, we aimed to summarize recent studies exploring their roles in pathophysiology of solid tumors and to provide insights into some complexities of their therapeutic applications.

【 授权许可】

CC BY   
© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.